By Chris Wack

Global Cord Blood Corp. shares were up 15% to $3.42 after the company said Cellenkos Inc. recently got U.S. Food and Drug Administration clearance for its Investigational New Drug application for CK0804.

This clearance allows Cellenkos to initiate a Phase 1b, open-label study of CK0804 as an add-on therapy to ruxolitinib in patients with myelofibrosis who experience a suboptimal response to ruxolitinib.

Global Cord Blood agreed to buy biotechnology company Cellenkos in April. At closing, Global Cord will issue 125 million new shares valued at $11 a share, and pay $664 million in cash.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

June 17, 2022 12:34 ET (16:34 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Global Cord Blood (NYSE:CO)
Gráfica de Acción Histórica
De May 2024 a Jun 2024 Haga Click aquí para más Gráficas Global Cord Blood.
Global Cord Blood (NYSE:CO)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024 Haga Click aquí para más Gráficas Global Cord Blood.